Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Integumen LSE:SKIN London Ordinary Share GB00BYWJ6269 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.005p +0.79% 0.64p 5,000,000 09:29:12
Bid Price Offer Price High Price Low Price Open Price
0.63p 0.65p 0.64p 0.635p 0.635p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
  0.24 -9.58 5.80 0.1 2.9

Integumen (SKIN) Latest News

More Integumen News
Integumen Takeover Rumours

Integumen (SKIN) Share Charts

1 Year Integumen Chart

1 Year Integumen Chart

1 Month Integumen Chart

1 Month Integumen Chart

Intraday Integumen Chart

Intraday Integumen Chart

Integumen (SKIN) Discussions and Chat

Integumen (SKIN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09:29:170.635,000,00031,500.00O
View all Integumen trades in real-time

Integumen (SKIN) Top Chat Posts

DateSubject
21/1/2019
08:20
Integumen Daily Update: Integumen is listed in the sector of the London Stock Exchange with ticker SKIN. The last closing price for Integumen was 0.64p.
Integumen has a 4 week average price of 0.49p and a 12 week average price of 0.40p.
The 1 year high share price is 1.38p while the 1 year low share price is currently 0.35p.
There are currently 454,826,872 shares in issue and the average daily traded volume is 739,192 shares. The market capitalisation of Integumen is £2,910,891.98.
21/1/2019
09:57
mulligut: Cross trade or not, 5m exchanged and share price rises. Nice Monday morning start
18/12/2018
08:37
dave4545: Shame the share price is not moving up though but trying to get buyers in December in quiet penny stocks is almost impossible. Very bearish out there Unchanged is the new +20%
13/12/2018
08:41
supertag: I read it thoroughly and am very disappointed that the RNS missed the mark in the following ways. First by saying it could help 3% of the market with skin problems, that should have stated an actual number of persons ,which I'm sure would be huge whereas 3% is a tiny number. The other killer in the RNS is where Gerard mentioned the END of 2019 for launch! That's why we won't see much movement in the share price. I have emailed the company with the above comments to express my disappointment in a missed opportunity. Supertag
03/12/2018
08:48
dave4545: Yump Then why not buy a decent stake and offer your expertise to them, if you can help them win more business then the share price will soar and you make money.
21/11/2018
15:48
mulligut: I suspect that people are getting fixated on diluting when the company is growing, as it appears to be. If the share price rises, then everyone wins, including the new CEO.
17/11/2018
15:33
74tom: Thanks for updating the summary Mulligut. I’m looking forward to the next trading update where hopefully we will get a split of the revenues by business unit. Re-reading the 27/9 RNS, the trading update for Labskin really stands out. “Since the half year end, sales for Labskin services have accelerated to a monthly run rate above the entire revenue of Labskin for the first six-months of 2018, which was £49,000.”; My stab at putting more detail on the estimated 2018 revenues; Labskin: If Labskin revenues were £49k+ per month and accelerating at the end of September, full 2018 revenues could look like; H1 - £49k - actual Q3 - £94k - Sep (£49k), Aug (£30k), Jul (£15k) Q4 - £150k - based on September run rate, leaving potential upside 2018 Total - £293k TSPro H1 revenues were £95k, however the August interims mentioned divestment was likely due to the high marketing cost required H2 estimate - £20k H2 could obviously be higher or lower, but wouldn’t expect it to drop to 0 straight away... Stoer Skincare We can calculate that H1 revenues couldn’t have exceeded £5k, so were tiny. However, Thursdays RNS is intriguing as it states Stoer is the main reason for the outperformance vs 2017... Impossible to say what this means from a revenue point of view for Stoer, but for the purpose of this exercise let’s assume a prudent £50k, but this could be significantly higher. Cellulac Then we have 50% of Cellulacs revenues to account for from 1st November. Unfortunately, the 2017 accounts filed at Companies House have redacted the turnover line. We do know that profit after exceptional items was £419k, so I’d estimate revenues of circa £1m but could be higher or lower than this... Assuming £1m for 2018, 2 months of revenues share would equate to £83k for SKIN. Visible Youth - another business to be divested, assume 0 revenues here. 2018 Revenue Summary Labskin : £293k TSPro : £115k Stoer Skincare : £55k Cellulac : £83k Total £546k H1 : £149k actual H2 : £397k estimate Of course costs are arguably more important, and we don’t have any guidance here. H1 EBITDA loss was £744k on revenues of £149k. If H2 costs remained the same (£744k + £149k = £893k) and revenue was £397k as my working above, EBITDA loss would be £496k. However, we know marketing costs for Stoer have been reduced whilst Visible Youth & TSPro have been sidelined, so in theory costs could be significantly lower than H1. If any of these estimates seem wildly out, feel free to correct them. Things are really looking up here in my opinion, another good trading update + the resolution of Nicholson/Meruriali issue, should result in the Share Price beginning to reflect the growth occurring in the business & the exciting future ahead...
16/11/2018
07:51
74tom: GJBrandon, thanks for taking the time to post here, I’d urge any potential investors to scroll back and read our CEO’s postings from July. It’s refreshing to see such direct communication. Even more positive to realise the predicted turnaround is really gaining traction. One poster in particular seems to have a huge issue with the directors being paid in shares at a competitive salary level. Personally, I would argue that this is a huge positive. Yes, if this time next year the share price was still at 0.4p, £220k of shares would mean some dilution. However, if the shares recover to near their IPO price the dilution would in fact be minimal. @GJBrandon, what would be great to see are some revenue/growth forecasts for 2019 and beyond, is there anywhere I can find this information at present? All in all, delighted I bought a substantial amount at open yesterday morning, fingers crossed the business can continue performing well, the share price will respond accordingly if it does!
22/9/2018
13:33
jimduggen: Goodluck gj brandon. Please keep dilution to a minimum and bring some value back to the share price asap. I am sure you will succeed. Keep your investors happy and well informed.
17/7/2018
13:05
gjbrandon: Buywell3. Mentioned above Alltracel spent £22 and 6 years bringing a range of wound care and skin care products to the market. Integumen had already completed all of that and were available for a valuation of £2m. Myself and my Chief Of Operations had to keep under 29% to avoid triggering a Reverse Takeover of Integumen. Cellulac's last transaction and funding round valuation in 2015 was £15m. Since then we concluded the signing of a 5-year offtake agreement for $36m and completed the commercial scale production of Omega 3 at a partner site in UK. These are documented on the Cellulac website. The share price of Cellulac at the last round was £1.00. The shares for Cellulac were swapped for Integumen shares at $0.50. This is public information. However we felt that agreement had been made at a higher valuation of Integumen, which we believed was fair, so we lowered the Cellulac share price, pro-rata to what had been agreed was fair value.
06/4/2017
13:34
mulligut: Rivaldo I am not a day trader so none of that particularly causes me any major concern. This is another share just like any other and hopefully based on what was done with Venn their management can drive value in the long term. I would expect that a decent newsflow regime for breakthrough products and distribution agreements will do a good bit for the share price. Long term it remains a very small part of my portfolio.
Integumen share price data is direct from the London Stock Exchange
Your Recent History
LSE
SKIN
Integumen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190121 14:19:07